amantadineAdjunctive therapyBrands: Symmetrel, Gocovri, Osmolex ER | Parkinson's disease; drug-induced extrapyramidal reactions; influenza A prophylaxis/treatment (label-dependent). View labelExact | Drug-induced extrapyramidal reactions: labeling commonly describes 100 mg twice daily, with some patients using 100 mg once daily depending on response and tolerability (label). | Dopaminergic/NMDA-modulating antiparkinson agent (also historically used as an antiviral) that can treat drug-induced extrapyramidal reactions, including antipsychotic-induced parkinsonism. Not an anticholinergic; may be considered when anticholinergic cognitive burden is a concern, balancing potential benefit against neuropsychiatric adverse effects and renal-dose constraints. | Not extensively metabolized; an N-acetylated metabolite has been identified (label). | Single-dose mean 17 h; Single-dose range 10–25 h | No | — | - Renal function and renal-dose appropriateness, especially in older adults and after intercurrent illness (label/clinical).
- Neuropsychiatric monitoring (sleep, agitation, hallucinations/confusion), particularly in patients with psychosis risk (label/clinical).
- Edema/skin monitoring (livedo reticularis) during longer courses (label/clinical).
| No | 2025-12-30 |
|---|
| Parkinsonism; control of extrapyramidal disorders due to neuroleptic drugs (except tardive dyskinesia) (label). View labelExact | Initiate with a low dose and increase gradually in 0.5 mg increments at 5–6 day intervals to the smallest amount necessary for relief; maximum labeled daily dose is 6 mg/day (label). | Anticholinergic (antimuscarinic) antiparkinson agent used for parkinsonism and to control extrapyramidal reactions caused by neuroleptic drugs (except tardive dyskinesia). In psychiatric practice it is often used short term for drug-induced parkinsonism or acute dystonia, balancing symptomatic benefit against anticholinergic adverse effects (confusion, constipation, urinary retention). | Hepatic metabolism (extent not well characterized in current labeling) (label/clinical). | No | — | - Anticholinergic adverse-effect monitoring (bowel function, urinary retention, blurry vision, dry mouth, tachycardia) (label/clinical).
- Mental status monitoring (confusion/delirium), especially in older adults or when anticholinergic burden is high (clinical).
- Screen for glaucoma risk and urinary obstruction symptoms when relevant (label/clinical).
- Periodic reassessment for TD symptoms and avoidance of anticholinergic treatment for TD when involuntary movements appear (label/clinical).
| No | 2025-12-30 |
|---|
| Parkinsonism (label). Common use includes control of antipsychotic-induced extrapyramidal reactions (label/clinical). View labelExact | Parkinsonism: labeling describes starting at 1 mg on day 1, then increasing by 2 mg increments at intervals of 3–5 days toward a typical daily total of 6–10 mg/day (label). | Anticholinergic (antimuscarinic) antiparkinson agent used for parkinsonism and to manage extrapyramidal reactions to antipsychotics. It can improve drug-induced parkinsonism and acute dystonia, but does not treat tardive dyskinesia and may worsen it; anticholinergic adverse effects often limit use. | Hepatic metabolism (extent not well characterized in current labeling) (label/clinical). | No | — | - Anticholinergic adverse-effect monitoring (bowel function, urinary retention, blurry vision, dry mouth, tachycardia) (label/clinical).
- Mental status monitoring (confusion/delirium), especially in older adults or when anticholinergic burden is high (clinical).
- Screen for glaucoma risk and urinary obstruction symptoms when relevant (label/clinical).
| No | 2025-12-30 |
|---|
propranololAdjunctive therapyBrands: INDERAL, INDERAL LA | Hypertension; angina pectoris; atrial fibrillation ventricular rate control; post-MI mortality reduction; migraine prophylaxis; essential tremor; hypertrophic subaortic stenosis; pheochromocytoma adjunct (label). View labelExact | Label dosing varies widely by indication (hypertension, arrhythmias, migraine prophylaxis). In psychiatric use, dose selection should be tied to the specific target symptom and the patient’s cardiopulmonary risk.
Performance anxiety (off label): low single doses taken before a time-limited event are common; start low and confirm tolerability with a trial dose (monitor heart rate, blood pressure, and dizziness). | Nonselective beta-adrenergic receptor blocker (beta-1/beta-2 antagonism). | CYP2D6, CYP1A2, CYP2C19, Glucuronidation | Single-dose range 3–6 h | No | — | - Check baseline heart rate, blood pressure, and asthma/COPD history before starting.
- Monitor bradycardia, hypotension, dizziness, and fatigue after dose changes.
- Reassess mood and sleep after initiation; discontinue or adjust if adverse effects outweigh benefit.
- Taper rather than stopping abruptly after sustained use, especially in coronary disease risk.
| No | 2025-12-29 |
|---|